Travere Therapeutics is Drug Discovery in United States that focus on Travere Therapeutics Inc business. Founded in 2011. They cover business area such as Travere Therapeutics Inc, commercialization, therapy, people, rare disease, its pipeline candidate, sparsentan, late-stage development, focal segmental glomerulosclerosis, FSGS, IgA nephropathy, (IgAN, rare kidney disorder, end-stage kidney disease.
2011
( 13 years old in 2024 )
Travere Therapeutics Inc
-
3611 Valley Centre Drive
Suite 200
San Diego, CA 92130
United States
Private
Travere Therapeutics Inccommercializationtherapypeoplerare diseaseits pipeline candidatesparsentanlate-stage developmentfocal segmental glomerulosclerosisFSGSIgA nephropathy(IgANrare kidney disorderend-stage kidney disease
* We use standard office opening hours in near Travere Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Travere Therapeutics is Drug Discovery business from United States that founded in 2011 (13 years old in 2024), Travere Therapeutics business is focusing on Travere Therapeutics Inc.
Travere Therapeutics headquarter office and corporate office address is located in 3611 Valley Centre Drive Suite 200 San Diego, CA 92130 United States.
Travere Therapeutics was founded in United States.
In 2024, Travere Therapeutics is currently focus on Travere Therapeutics Inc sector.
Above is snippet of Google Trends for "Travere Therapeutics Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Travere Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
